Mei Sheng Duh, R Ph, Mph, Sc D
About Mei Sheng Duh, R Ph, Mph, Sc D
Mei Sheng Duh is the Managing Principal and Chief Epidemiologist at Analysis Group, Inc., and a Visiting Scientist at Harvard School of Public Health. He specializes in real-world evidence generation and has extensive experience in pharmacoepidemiology and health economics.
Company
Mei Sheng Duh is currently a Managing Principal (Partner) and Chief Epidemiologist at Analysis Group, Inc. in Greater Boston Area, where she has been working since 2001. She provides expert epidemiological consulting services, focusing on health economics, outcomes research, and drug safety epidemiology, particularly in the context of pharmaceutical product liability litigations.
Title
Mei Sheng Duh holds the title of Managing Principal (Partner) and Chief Epidemiologist at Analysis Group, Inc. In addition, she serves as a Visiting Scientist in Biostatistics at the Harvard School of Public Health.
Education and Expertise
Mei Sheng Duh has an impressive educational background, having earned a Doctor of Science (ScD) degree in Pharmacoepidemiology from Harvard University School of Public Health, an MPH in Epidemiology from Yale University School of Medicine, and a BS in Pharmacy from Kaohsiung Medical College, Taiwan. She also holds the professional qualification of Registered Pharmacist (RPh). Her expertise encompasses real-world evidence generation for pharmaceuticals, vaccines, and regenerative biotherapeutics.
Background
Over her career, Mei Sheng Duh has accumulated extensive experience in the pharmaceutical industry and academia. She worked as a Senior Associate at Ingenix Pharmaceutical Services (i3 Drug Safety) from 1999 to 2001 and as an Epidemiologist at AstraZeneca from 1996 to 1999. Besides her industry roles, she contributes to academia as a guest lecturer in the Epidemiology department at Harvard University School of Public Health and serves as an adjunct in the Biostatistics department at Harvard T.H. Chan School of Public Health.
Achievements
Mei Sheng Duh has numerous achievements, including being appointed to an expert panel by the Foundation for the National Institutes of Health’s Observational Medical Outcomes Partnership. She has also served as a peer reviewer for several leading journals and has been an elected member of various prestigious societies such as the American Society of Hematology and the American Society of Clinical Oncology. Her publication record is extensive, with over 290 peer-reviewed publications.